Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia
Annals of Hematology, 08/20/2012
Song LX et al. – The authors conclude that induction therapy with decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for refractory/relapsed de novo acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)/AML achieved high levels of complete remission (CR)and improved overall survival (OS) and demonstrated adequate tolerance. Moreover, the decitabine component of DAA may function through a demethylation effect.